Clemastine fumarate

  • Aloginan
  • Alphamin
  • Anhistan
  • (+)-2-(2-((p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl
  • Pyrrolidine
  • 2-(2-(1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine
Formula
C21H26ClNO.C4H4O4
Structure
Description
Colorless to faintly yellow crystalline powder. Odorless.
Uses
Medication.

Registry Numbers and Inventories.
CAS
14976-57-9
EC (EINECS/ELINCS)
239-055-2
RTECS
UY0704600
RTECS class
Drug
Beilstein/Gmelin
4118973
Beilstein Reference
5-21-01-00115

Properties.
Formula
C21H26ClNO*C4H4O4
Formula mass
460.01
Melting point, °C
176 - 180
Boiling point, °C
154 (0.02 torr)
Solubility in water
Slightly soluble

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Rapid heart rate is common. Elevated body temperature, abnormally low blood pressure, and elevated blood pressure have been reported. overdose may result in either CNS depression, including coma, or CNS stimulation, such as toxic psychosis. Subsequent seizures are not uncommon, especially in children. A higher incidence of seizures has been reported following pheniramine overdoses. Therapeutic use has been associated with acute dystonic reactions and dyskinesias. In general, there have been few reported teratogenic effects in humans, although animal studies have suggested that certain antihistamines have teratogenic potential. <br>Pyloric stenosis has occurred in infants following maternal use of antihistamines. <br>Small amounts of antihistamines are excreted in breast milk.
   Ingestion
Overdose may cause anticholinergic effects of ileus and diminished bowel sounds. Nausea, vomiting, and loss of appetite may occur .
   Inhalation
Pneumonitis, chest tightness, and wheezing have been reported.
   Eyes
Anticholinergic effects, such as prolonged dialation of the pupils, nasal dryness and stuffiness, and mouth and throat dryness, can occur with overdose or therapeutic use.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.

Transport.